ArticleBMC pulmonary medicine2026
Clinical factors and practical strategies to optimize amikacin liposome inhalation suspension therapy in refractory Mycobacterium avium complex pulmonary disease.
Article in BMC pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAmikacin liposome inhalation suspension (ALIS) has been used in several countries including Japan for refractory Mycobacterium avium complex pulmonary disease (MAC-PD). Although its efficacy and adverse events have been reported, factors that limit optimal treatment outcomes in real-world practice are not fully understood. Therefore, we aimed to provide practical considerations for optimizing ALIS therapy by identifying factors associated with culture conversion.
methodsWe retrospectively reviewed the medical records of patients with refractory MAC-PD who were treated with ALIS at a single center between October 2021 and June 2025. Patients treated for ≥ 6 months were included and categorized into culture conversion and non-conversion groups. Clinical characteristics and treatment-related factors were analyzed. Follow-up continued until December 2025.
resultsDuring the study period, 30 patients with refractory MAC-PD were treated with ALIS. Three patients who discontinued ALIS within 6 months were excluded from further analysis because of MAC-related death (n = 1) or severe ALIS-related adverse events (n = 2). Consequently, 27 patients were included in the analysis. The median age was 69.9 years, and the median duration of ALIS therapy was 14.6 months. The sputum culture conversion rate was 51.8% (14/27; 95% CI, 34.0-69.3%). Pulmonary fungal disease was identified in 7 patients (25.9%), including newly diagnosed cases during ALIS therapy; however, pulmonary fungal disease was not significantly associated with culture conversion. Cavitary lesions and prior aminoglycoside use were significantly associated with non-conversion. In addition, inappropriate ALIS administration, including prolonged intermittent use and inadequate nebulizer handset replacement, was significantly associated with non-conversion. Dysphonia was the most frequent adverse event and occasionally led to prolonged intermittent use of ALIS. ALIS-related lung abnormalities on computed tomography (CT) scans were observed in 21 of 26 patients.
conclusionsCavitary lesions, prior aminoglycoside use, and inappropriate ALIS administration were associated with culture non-conversion. Several factors related to ALIS administration and inhalation management may be modifiable, and appropriate patient education, regular reassessment of inhalation practices, and careful monitoring of ALIS administration may help optimize treatment outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.